CTOs on the Move

Signant Health

www.signanthealth.com

 
We help you connect patients and researchers to ensure data reliability, with proven solutions that simplify every step of the patient journey. Our deep therapeutic area expertise, agile technology and service scale enable us to minimize risk, innovate, and support your important work. We seek speed, efficiency and reduced variability to help you extend the reach of drug development, expand patient opportunities and improve data quality helping you bring life-changing therapies to our families and communities around the world.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Paul Drake
Chief Security Officer Profile
George Moore
Chief Technology Officer Profile
Lawrence Miller
Chief Technology Officer Profile

Similar Companies

Natrol subsidiary of Plethico Pharmaceuticals Limited

Natrol, Inc. subsidiary of Plethico Pharmaceuticals Limited is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flexicon America

Flexicon America is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bibb County School District

Bibb County Public Schools is the county government agency which operates the public schools in Bibb County, Georgia, United States.

Duramed Pharmaceuticals

Duramed Pharmaceuticals is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.